“Cure's flagship: a full 6-inch face with adjustable weights from 361 to 615 grams, reaching an 18000 MOI rating the brand calls the highest in golf. Maximum stability and face-balanced for a straight stroke.”
The RX5 is Cure's flagship, the biggest putter the brand makes with a full 6-inch face. With the extended weight kit installed, its adjustable weights run from 361g up to 615g, and at that top weight Cure rates the head at 18,000 MOI — a number the company markets as the highest in golf. It's the maximalist expression of the same platform as the RX3/RX4: aircraft-aluminum construction, a fully adjustable hosel, and interchangeable toe/heel weights, just scaled up to push the MOI ceiling as high as the format allows.
The '18,000 MOI, highest in golf' claim gives the RX5 a genuine specialty-press talking point (Golf Tips, ColoradoGolfBlog, engineered-golf retailer copy all repeat it), but it hasn't crossed into mainstream cultural relevance or tour use, and Cure remains a small independent brand rather than a household name. It's a real superlative within a real niche, not a broader phenomenon.
For a player who has fully committed to forgiveness-first putting — high handicappers, players managing hand/wrist/back limitations who want maximum stability and are unconcerned with a large, visually bold head at address. Not for anyone who wants feel, a compact look, or the ability to manipulate face angle through the stroke.
Released a year after the RX3/RX4 as the range-topper, riding the same high-MOI mallet wave as Odyssey's Ten and TaylorMade's Spider line but going further on sheer size and adjustable mass than those tour-driven competitors were willing to, since Cure wasn't chasing pro-shop shelf appeal.
At the top of its adjustable range this is about as forgiving as a putter gets on the current market — Cure's own 18,000 MOI claim, if accurate, exceeds most mainstream mallets by a wide margin, and the 6-inch face is the largest in the RX line. This is a case where the marketed superlative and the actual physics point the same direction: bigger, heavier, more MOI equals more twist resistance on off-center hits.
Calibrated across the whole catalog — a tour blade scores low here on purpose; it means control, not ease.
Roughly $130-200 in 2026 on the private-party market against a $299 original MSRP, the top of the RX pricing tier reflecting both the bigger original price and the flagship-model draw among the small pool of Cure buyers.
Reading is one thing — hitting is another. Book a bay and see the numbers for yourself before you buy anywhere.
